Angiotensin II receptor antagonists in the treatment of hypertension

American Family Physician

Volumn 60, Issue 4, 1999, Pages 1185-1190

  Kaplan, Norman M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; TELMISARTAN; VALSARTAN;

ALGORITHM; ARTICLE; CARDIOVASCULAR RISK; COUGHING; HUMAN; HYPERTENSION; TREATMENT INDICATION;

ALGORITHMS; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; HUMANS; HYPERTENSION; LOSARTAN; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VALINE;

EID: 0033568814     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 1997;157:2413-46 [Published erratum in Arch Intern Med 1998;158:573].
2. Kaplan NM. Clinical hypertension. 7th ed. Baltimore: Williams & Wilkins, 1998.
3. Kaplan NM. Treatment of hypertension: insights from JNC-VI report. Am Fam Physician 1998;58: 1323-30.
4. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-83.
5. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64.
6. Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18:797-810.
7. Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine, Clin Pharmacol Ther 1996;60:341-6.
8. Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997;11:483-9.
9. Neutel J, Weber M, Pool J, Smith D, Fitzsimmons S, Chiang YT, et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997;19:447-58.
10. Benz J, Oshrain C, Henry D, Avery C, Chiang YT, Gatlin M, Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997;37:101-7.
11. Chan P, Tomlinson B, Huang TY, Ko JT, Lin TS, Lee YS. Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol 1997; 37:253-7.
12. Johnston Cl, Burrell LM. Evolution of blockade of the renin-angiotensin system. J Hum Hypertens 1995;9:375-80.
13. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in Elderly Study, ELITE). Lancet 1997;349:747-52.
14. Azizi M, Guyene TT, Chatellier G, Wargon M, Menard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997;29:634-40.
15. Schmitt F, Natov S, Martinez F, Lacour B, Hannedouche TP. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man. Clin Sci [Colch] 1996;90:205-13.
16. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54.